BEACON ASIA TOUR |
Join us in Singapore at SIgN, A*STAR
Overview
Experience the full potential of live single-cell functional analysis and discover how researchers use Beacon technology to accelerate discoveries and unlock new insights.
Powered by advanced optofluidics, every Beacon instrument lets you track multimodal, time-resolved cellular responses in real timeโseamlessly pairing functional data with sequencing from the very same cell.
Explore Beacon Discoveryโข, our new benchtop platform that packs these powerful optofluidic capabilities into a more accessible and compact package.
Speakers
Dr. Patrick Schmidt
Group Leader Transgenic T Cell Therapy, DKFZ
Dr. rer. nat. Patrick Schmidt is a senior scientist with 20 years of experience in CAR-T research. He completed his undergraduate studies in Developmental Biology and Genetics at the University of Cologne, earning his diploma in 2005. He conducted his Ph.D. research in Hinrich Abken's lab, developing anti-melanoma CARs, and finished in 2008. This was followed by a three-year DFG fellowship-sponsored postdoctoral position at the รcole Polytechnique Fรฉdรฉrale de Lausanne in Switzerland. In 2014, Patrick joined the Department of Medical Oncology at the National Center of Tumor Diseases Heidelberg, led by Dirk Jรคger. He is currently a research group leader and head of ATMP manufacturing, affiliated with the University Hospital Heidelberg and the German Cancer Research Center.
Dr. Kah Fei Wan
Head of Antibody Technology Division Experimental Drug Development Centre The Agency for Science, Technology and Research (A*STAR)
Dr. Kah Fei Wan is a pharmacist and PhD in pharmacology with over 15 years of drug discovery experience in pharmaceutical industry and public research entities. He has demonstrated proven track record in managing functional teams across various disciplines including small and large molecule high-throughput hit-to-lead finding platform. As a project leader, he has developed and executed strategies, provides direct project leadership and management skills leading external and local matrixed teams of scientists, and successfully led therapeutic lead identification efforts to reach clinical, out-licensing and new start-up milestones. He brings extensive expertise in target nomination, due diligence, and scientific writing for both small and large molecule programs, spanning a range of therapeutic areas including oncology, ophthalmology, fibrosis, and infectious diseases.
Dr. Jianxin Huo
Principal Scientist
Co-Director, Single Cell Cloning Platform
Singapore Immunology Network (SIgN)
The Agency for Science, Technology and Research (A*STAR)
Co-Director, Single Cell Cloning Platform
Singapore Immunology Network (SIgN)
The Agency for Science, Technology and Research (A*STAR)
Dr. Jianxin Huo holds a Ph.D. in Biochemistry from the National University of Singapore and has extensive experience in immunology and biotechnology. He specializes in single-cell biology and immunotherapeutic antibody development. With over twenty five years of research experience, he has contributed significantly to the understanding of immune regulation and cancer biology. Dr. Huo has authored numerous publications in top scientific journals. His expertise spans T-cell immunotherapy, inflammation, and metabolic disorders. Currently, he co-leads the Single Cell Cloning Platform at SIgN, focusing on cutting-edge biotechnological innovations.
Dr. Ryan Chong
Director of Business Development, APAC, Twist Bioscience
Dr. Ryan Chong is a biotechnology expert with deep expertise in antibody discovery and development. He holds a Ph.D. in Microbial Pathogenesis from Yale and completed a postdoctoral fellowship at Genentech. Currently Director of Business Development at Twist Biopharma Solutions, he has held key leadership roles at Abcam Danaher driving scientific and commercial growth across Asia. His background spans antibody engineering, immunoassay development, and biotherapeutics, making him a trusted leader in advancing antibody-based research.